Key Stats for CHE Stock
- Price Change for CHE stock: -15%
- CHE Share Price as of Feb. 26: $397
- 52-Week High: $624
- CHE Stock Price Target: $556
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>
What Happened?
Chemed (CHE) stock fell 15.0% on February 26 after the company reported Q4 2025 results. Shares closed at $397, just above the 52-week low of $385. The decline followed an earnings miss and softer segment performance.
Chemed reported Q4 adjusted EPS of $6.42 versus the IBES estimate of $7.07. Revenue also missed analyst expectations, according to Reuters. Investors reacted negatively to the earnings shortfall.
At the Roto-Rooter segment, Q4 adjusted EBITDA declined 21.1% to $47.5 million. That margin pressure weighed on overall profitability. Meanwhile, the company continues to operate its VITAS hospice business nationwide.
Despite the short-term setback, Chemed maintains a long history of steady cash flow generation. However, the earnings miss appears to have triggered near-term selling pressure.
See analysts’ growth forecasts and price targets for CHE stock (It’s free!) >>>
What the Market Is Telling Us About CHE Stock
Chemed operates through its VITAS hospice care and Roto-Rooter plumbing services segments. The business model blends healthcare services with residential and commercial service operations. That diversification has historically supported stable returns.
From a financial perspective, Chemed remains conservatively structured. LTM net debt stands at $69 million, and net debt to EBITDA is just 0.15x. Enterprise value is $5.7 billion versus a $5.6 billion market cap.
Profitability metrics remain strong despite the earnings miss. LTM EBIT margin is 13.4%, while ROE stands at 25.3%. ROIC is 29.6%, which reflects efficient capital allocation.
The stock’s 5-year beta is 0.46, which suggests lower volatility than the broader market. However, the sharp single-day drop shows earnings surprises can still move shares meaningfully.
Estimate a company’s fair value instantly (Free with TIKR) >>>
Should You Invest in Chemed Corporation?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up CHE, and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track CHE alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Analyze Chemed stock on TIKR Free→
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
